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The seventh report of the joint national committee (JNC7) on
prevention, detection, evaluation, and treatment of high blood
pressure defines hypertension as blood pressure (BP)  140/
90 mmHg. Hypertension affects nearly 1 billion of the global
adult population and 26.4% of the adult population in 2000 had
hypertension. The projected prevalence rate is 29.2% with
absolute no. of 1.56 billion by 2025.1 Though there is a lack of
systemic data on prevalence of hypertension in India, pooling5.
zeneca.com (H. Vasnawa
ciety of India. All rightsof many epidemiological studies reveals that hypertension is
prevalent in 25% of urban and 10% of rural subjects.2 Hyper-
tension is one of themost important independent predictor of
cardiovascular disease and cerebrovascular events. It ac-
counts for an estimated 54% of all strokes and 47% of all
ischemic heart disease events globally.3
Blood pressure is regulated by a complex interaction be-
tween various physiological systems and among them it is
well established that Sympathetic Nervous System (SNS)
plays a vital role. The last decade has seen a new and more
complex picture emerging of the SNS as a key controller of thela).
reserved.
Fig. 1 e Influence of sympathetic overactivity on various systems.
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thetic overactivity (SO) plays an important role in the devel-
opment of both hypertension and its related cardiovascular
disorders.4 SO causes an increase in heart rate, cardiac output,
peripheral vascular resistance, and sodium reabsorption in
the kidney and a consequent elevation of systemic BP (Fig. 1).5
It is also found to be associated with prolongation of cardiac
repolarisation time in hypertensive patients with morning BP
peaks. It may play a critical role in increasing cardiovascular
risk in such patients.6 SO in hypertension is also conducive
to coronary heart disease through its association with high
hematocrit values and excessive platelet agreeability.7
In the given context of the role of SO in hypertension and
the associated CV risk there is an acute need to study the
prevalence of SO in India. Also it is extremely important to
clearly identify symptoms of SO in patients with newly-
diagnosed essential hypertension so that proper measures
can be instituted early enough to control the same. The pri-
mary aim of this study was to assess the prevalence of SO in
patients with newly diagnosed primary hypertension.2. Materials and methods
Study Design: This is a multi centre, non interventional, cross
sectional, pan India epidemiological study to estimate the
prevalence of SO in patients with newly diagnosed essential
hypertension. Data collection for each subject took place at
three visits, with a gap of four weeks between each visit.Treatment including lifestyle modification and anti-hyper-
tensives was at the discretion of the treating physician during
the study. The assignment of a subject to a particular thera-
peutic strategy was not decided in advance by a protocol but
fell within current clinical practice. Commercially available
anti-hypertensive drugs were used during this study.
The study was conducted in accordance with the Interna-
tional Conference on Harmonisation-Good Clinical Practice
(ICH GCP) guidelines and the ethical code of conduct laid out
by declaration of Helsinki and Indian Council of Medical
Research (ICMR) guidelines. Written informed consent was
taken from all participating subjects. The study was approved
by Clinicom, an independent ethics committee in Bangalore.
Drug Controller General of India (DCGI) was notified as per
existing regulatory requirement in India. The study was
registered with ClinicalTrials.gov (NCT01295021). Due to the
non-interventional nature of this study, though no pro-active
safety data was collected, spontaneous safety events were
reported.
Inclusion and exclusion criteria are listed below in Table 1.
Statistical Analyses: Descriptive statistics was used for all
demographic variables. Statistical hypothesis testing using
chi square test and likelihood ratio chi-square test were con-
ducted to find out whether any statistically significant asso-
ciation exists between the variables tested. 5% level of
significance was considered as statistically significant. T-test
was performed to test the significance of association between
mean change in systolic and diastolic blood pressure and
mean change in heart rates from first visit to third visit.
Table 1 e Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
 Men and women aged 18 years of age
with newly diagnosed primary hypertension
(SBP  140 mmHg, DBP  90 mmHg as per
JNC 7 Criteria) will be eligible for the study.
 Provision of subject informed consent
 History of coronary artery disease
 History of diabetes
 History of malignancy
 Current active liver disease or ALT levels >3 times the upper Limit of Normal (ULN).
 Unexplained creatine kinase (CK) levels > 10 times ULN.
 History of chronic kidney disease
 Uncontrolled hyperthyroidism
 History of alcohol or drug abuse within the last 5 years
 Initiation of hormone e replacement therapy or oral contraceptives within 3 months
of enrollment.
 Currently on treatment with any drug which can affect BP or resting heart rate
 Pregnant or breastfeeding women
 Refusal to sign informed consent forms
 If participating in any clinical trial, the subject cannot take part in this study
Table 4 e BP and HR during the study period.
BP/HR Visit n Mean (SD)
BP e systolic Visit 1 1514 160.33 (14.64)
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The study was carried out on 1514 newly diagnosed hyper-
tensive patients (63.58% males, 35.62% females). The baseline
data is presented in Table 2. The Body Mass Index (BMI) ob-
servations in the study were grouped according to the Indian
guidelines issued by Ministry of Health.8 Among the study
population for whom BMI could be calculated, 65.07%
belonged to the ‘Obese’ category, and another 18.51% to the
‘Overweight’ category. In the studywe observed that 18.02% of
the patients were smokers and 47.44% had a family history of
hypertension.
Of the 1514 subjects, 945 had symptoms of SO and thus the
prevalence of SO in the study population was 62.42% Table 3
gives a detailed distribution of the different symptoms of SO
observed by investigators in this study. A patient may have
more than one symptom of SO and therefore there could be
overlaps in the data. We observed 43.20%, 29.52%, 22.19% and
12.09% of the study population had symptoms of restlessness,
inappropriate sweating, tremor in hands and fast speech
respectively.Table 2 e Baseline characteristics.
Variable Mean
Age (yrs) 47.94
Height (cm) 163.25
Weight (kg) 71.29
BMI (kg/m2) 27.29
Table 3 e Proportion of study population with various
symptoms of SO.
Sympathetic overactivity
Symptoms n (%)
Restlessness 654 (43.20)
Inappropriate sweating 447 (29.52)
Tremors in hands 336 (22.19)
Fast speech 183 (12.09)Blood pressure and heart rate data at first visit was avail-
able for 1514 and 1502 patients respectively. Themean systolic
BP, diastolic BP and heart rate were 160.33 mmHg,
97.29 mmHg and 90.12 beats per minute (bpm) respectively.
Table 4 provides the details for all the three study visits in
terms of BP and HR.
The mean change in systolic and diastolic blood pressure
and Heart rate between first and second visits, second and
third visits and first and third visits have been tabulated in
Table 5. Overall, the trend shows a good control in the man-
agement of hypertension and heart rate.
We found a statistically significant association between
heart rate and hypertension in all the three visits (p  0.0001).
We also found out statistically significant association between
SO and heart rate in first and second visits (p  0.0001) but notVisit 2 1506 142.89 (12.67)
Visit 3 1501 133.09 (10.44)
BP e diastolic Visit 1 1514 97.29 (7.12)
Visit 2 1506 87.82 (6.13)
Visit 3 1501 82.88 (5.27)
Heart rate Visit 1 1502 90.12 (10.41)
Visit 2 1488 81.95 (7.89)
Visit 3 1479 77.43 (6.74)
Table 5 e Mean change in systolic and diastolic blood
pressures and Heart Rate across visits.
Variable Visit n Mean (SD)
bp e systolic Visit 1e2 1506 17.69 (13.28)
Visit 2e3 1499 9.65 (8.9)
Visit 1e3 1501 27.34 (14.31)
BP e diastolic Visit 1e2 1506 9.48 (7.3)
Visit 2e3 1499 4.95 (5.56)
Visit 1e3 1501 14.43 (7.75)
Heart rate Visit 1e2 1488 8.21 (8.42)
Visit 2e3 1474 4.52 (6.22)
Visit 1e3 1479 12.74 (10.52)
Fig. 2 e Most commonly prescribed anti-hypertensive drugs.
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patients who had symptoms of SO fall under the BMI category
of ‘Obese’. However, we did not find any statistically signifi-
cant association between SO and BMI or age.
We also studied the association between SO and hyper-
tension across all three visits. In the first and third visits we
did not find any statistically significant association, however,
a significant association (p¼ 0.0125) was observed in 2nd visit.
Themost commonly prescribed anti-hypertensive drugs in
the study population were Metoprolol alone, followed by
Metoprolol in combination with Amlodipine, Amlodipine
alone, Olmesartan alone, and Metoprolol in combination with
Olmesartan. Fig. 2 represents the prescription of these drugs
for all the three visits combined. The average reduction in
systolic and diastolic blood pressure from the first to the third
visit for patients on Metoprolol (n ¼ 613) was 24.61 and
13.99 mmHg respectively. The average reduction in heart rate
for this particular subpopulation was found to be 14.53 bpm.
No serious adverse event was reported in this study.4. Discussion
With increasing recognition about the role of SO in the path-
ophysiology of hypertension and associated cardiovascular
complications, it is of utmost importance to address the need
for generation of Indian data on the prevalence and man-
agement of SO in newly diagnosed hypertensives. In a country
where one among four urban dwellers is a hypertensive and
70% of them in stage I hypertension, it is imperative to effec-
tively control the BP and take proactive measures to minimize
the associated CV risk. Our study result shows prevalence of
SO in newly diagnosed hypertensive patients in India to be
62.42%.
This data is in line with data from Smith et al study which
showed that central sympathetic activity was highest in
borderline hypertension, early stage, and complicated essen-
tial hypertension, and this activity was likely to play an inte-
gral role in the development of hypertension and its
complications.9
We now know that at least six out of ten newly diagnosed
hypertensive patients in India have SO. We hypothesize a
convergence in the management of hypertension through
therapeutic intervention of SNS and cardiovascular system,
and we believe this will be one of the emerging treatmenttargets in the near future. In clinical practice, physicians
should look for symptoms like restlessness, inappropriate
sweating and tremors in hands as indicators for SO while
treating patients with hypertension. As our results suggest,
these were the highest reported symptoms in patients with
SO. Our results point towards the correlation between SO and
heart rate and also between SO and hypertension. Our study
results will encourage physicians to take amore proactive role
in identifying and managing SO for improved cardiovascular
outcomes in newly diagnosed hypertensives.
We must admit that this research has some limitations.
Due to the real world setting of the study, we had few patients
lost to follow up, some drop outs and therefore unavailability
of the same pool of patients for all the analysis of different
parameters. Though a controlled clinical trial would have
helped address these challenges, as our aimwas to obtain real
world Indian data in a cross sectional setting, we opted for this
study design. While we do acknowledge the study limitations,
we believe the outcome is still invaluable in the context of SO
and hypertension in India. Further research is necessary to
arrive at concrete causal and mechanistic relationships be-
tween the two. We hope that our research will pave the way
for more such initiatives.Conflicts of interest
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